Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
about
Early phase clinical trials to identify optimal dosing and safetyStatistical controversies in clinical research: requiem for the 3 + 3 design for phase I trialsIntegrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screenAdaptive dose-finding studies: a review of model-guided phase I clinical trials.Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents.Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations.A Selective Small Molecule DNA2 Inhibitor for Sensitization of Human Cancer Cells to ChemotherapyChoice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.Interplay of priors and skeletons in two-stage continual reassessment method.Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.Phase 1 trial design: is 3 + 3 the best?The changing landscape of phase I trials in oncology.Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in JapanThe war on cancer: have we won the battle but lost the war?Systems pharmacology strategies for anticancer drug discovery based on natural products.Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns.Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients.Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.
P2860
Q26865076-48F26008-D69F-4B13-8425-51842352D30FQ27023178-D9043505-DE6C-4EEB-A61A-E5D14D10EA17Q28484181-283F1C79-D96A-4A7B-B108-148E8E8F83E7Q34001009-3DA89B07-43E1-4488-A364-59C919F88579Q34516049-C08E39DA-725E-49A8-8EDC-B18393584F7EQ34684352-D20010EE-E8D3-451F-9661-0562DA431566Q36025829-6C860269-32C2-428D-8BC9-25D5A9443546Q36064870-158782E8-52A6-43A1-873B-7303EF48F482Q36513919-DF08D141-CF53-45B5-A9DD-A6C246A305F0Q37129865-734C9A27-4FD5-49CF-98DE-C69AD934856EQ37496388-B3537F42-650A-4899-B54B-F90032BBB6A7Q37552670-C4F9E838-E30B-41CA-9F7C-E0BEBCA6CAFEQ38222466-2AF0EC38-50CC-463A-A989-5963B7F1E32AQ38629203-CFEBA606-61C4-4C26-9F1D-A94EDB9000CFQ38907890-F1756B3A-B4BA-4685-BF0C-C6E953771C26Q42419701-87D566A9-1382-408C-8C90-A06E15BAEB09Q43889374-346281E8-B2F2-474B-BBE1-1DCE2849C1AEQ44209463-68E42533-2169-4D33-966F-DD4085419A99Q45994683-1292C453-E951-4F4E-9364-311F7E4E31BAQ47223679-EE56E035-8964-44B0-AE98-07FA9914B511
P2860
Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Choice of starting dose for mo ...... hase I cancer clinical trials.
@en
Choice of starting dose for mo ...... hase I cancer clinical trials.
@nl
type
label
Choice of starting dose for mo ...... hase I cancer clinical trials.
@en
Choice of starting dose for mo ...... hase I cancer clinical trials.
@nl
prefLabel
Choice of starting dose for mo ...... hase I cancer clinical trials.
@en
Choice of starting dose for mo ...... hase I cancer clinical trials.
@nl
P2093
P356
P1476
Choice of starting dose for mo ...... hase I cancer clinical trials.
@en
P2093
Anastasios Stathis
Laura Vidal
Lillian L Siu
Malcolm J Moore
P304
P356
10.1200/JCO.2009.25.9606
P407
P577
2010-02-01T00:00:00Z